Recent News

Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer

PET Imaging of Mitochondrial Activity in Lung Tumor Cells

FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer

Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?

ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer

RSNA 2019: Deep Learning Tool and Cardiovascular Health on Lung Cancer Screenings

Atezolizumab/Chemotherapy Approved by FDA in First-Line Treatment of Metastatic Lung Cancer

Case Studies: Possible Link Between Nivolumab for Lung Cancer and Pericardial Effusion

Final Overall Survival With Atezolizumab/Chemotherapy in Advanced Lung Cancer

Early Study Findings With Novel KRAS Inhibitor in Advanced Lung Cancers

SITC 2019: Atezolizumab Monotherapy Versus Chemotherapy in PD-L1–Selected Lung Cancer

ASCEND-7: Ceritinib for Brain Metastases From ALK-Positive Lung Cancer

3-Year Survival Update of KEYNOTE-024: Comparison of Pembrolizumab and Chemotherapy

Prognostic Indicators Among Patients With EGFR-Positive NSCLC

Investigational Drug Under Study in KRAS G12C–Mutant Lung Cancer

Mutations Linked to Poorer Outcomes in Lung Cancer Identified in MYSTIC Trial

ESMO 2019: Tissue Tumor Mutational Burden and Survival With Pembrolizumab in Lung Cancer

ASCO Breakthrough 2019: Lung Cancer Diagnosis Tool Takes CAD to New Dimensions

ESMO 2019: Liquid Biopsy May Guide Therapy for Some Patients With Lung Cancer

First-in-Human Trial of Anti-AXL Antibody-Drug Conjugate in Advanced Lung Cancer

ESMO 2019: First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC

WCLC 2019: Comparison of Screening Methods for Those at Risk of Lung Cancer

WCLC 2019: Blood Biomarker–Based Lung Cancer Screening

ESMO 2019: Combination Immunotherapy Versus Chemotherapy in Advanced Lung Cancer

ASTRO 2019: Adding SBRT to Pembrolizumab in Metastatic Lung Cancer

WCLC 2019: First Results Reported From the National Lung Matrix Trial

WCLC 2019: VIOLET Study Reports Benefits of VATS vs Open Lobectomy

WCLC 2019: Tumor Mutational Burden and Treatment Efficacy With Pembrolizumab

Tepotinib Granted Breakthrough Therapy Designation in Subtype of Metastatic NSCLC

WCLC 2019: LIBRETTO-001 Trial Reveals Antitumor Activity of RET Inhibitor

ASTRO 2019: Characterizing Patterns of Disease Progression in Stage III Lung Cancer

Capmatinib Granted FDA Breakthrough Therapy Designation for MET-Mutated Advanced NSCLC

Quality Care 2019: Why Do Some Patients With Lung Cancer Delay TKI Treatment?

WCLC 2019: 5-Year Overall Survival With Nivolumab From CheckMate Trials

WCLC 2019: Real-World Data on Sequential Therapy for ALK-Positive Lung Cancer

WCLC 2019: Final Data From ALUR Trial of Alectinib in Pretreated Lung Cancer

Quality Care 2019: Out-of-Pocket Costs of Oral Agents and Outcomes in Advanced Lung Cancer

Quality Care 2019: Clinical Trial Enrollment and Survival in Metastatic Lung Cancer

Detecting Brain Metastases in Patients With Lung Cancer: Comparison of Imaging Modalities

EMERGING-CTONG 1103 Trial: Neoadjuvant Erlotinib in EGFR-Mutant Lung Cancer

Entrectinib Approved by FDA for ROS1-Positive NSCLC

Two-Drug Combination Targets Resistance in Cancer

Early Results With Dual Inhibition of VEGFR2 and PD-1 in Advanced Lung Cancer